Drug identification and treatment method
View Patent ↗The invention relates to methods to identify compounds that can treat autoimmune conditions and treat specified clinical disorders such as multiple sclerosis, ulcerative colitis or arthritis. Compounds include 17α-ethynylandrost-5-ene-3β,11β,7α,17β-tetrol, 4α-acetoxy-17α-ethynylandrost-5-ene-3β,7β,17β-triol, 17α-ethynylandrost-5-ene-3β,4β,7α,17β-tetrol, 17α-ethynylandrost-5-ene-3α,4β,7α,17β-tetrol and 17α-ethynylandrost-5-ene-3α,4β,17β-triol-7-one.
1. A method to treat inflammation in a patient in need thereof, comprising oral administration of 17α-ethynylandrost-5-ene-3β,7β,17β-triol to the patent in an amount sufficient to maintain a serum level of about 1 ng/mL to about 250 ng/mL for at least about 30 minutes to about 8 hours.
2. The method of claim 1 wherein about 5 mg/day to about 80 mg/day of 17α-ethynylandrost-5-ene-3β,7β,17β-triol is administered.
3. The method of claim 2 wherein about 5 mg/day to about 40 mg/day of 17α-ethynylandrost-5-ene-3β,7β,17β-triol is administered.
4. The method of claim 2 wherein the inflammation is an inflammatory bowel disease.
5. The method of claim 2 wherein the patient has a lung inflammation condition.
6. The method of claim 4 wherein the patient has an inflammatory bowel disease and the inflammatory bowel disease is ulcerative colitis, Crohn's disease or irritable bowel syndrome.
7. The method of claim 5 wherein the patient has a lung inflammation condition and the lung inflammation condition is cystic fibrosis, chronic bronchitis, emphysema, adult respiratory distress syndrome, asthma or chronic obstructive pulmonary disease.
8. The method of claim 7 wherein the lung inflammation condition is emphysema.
9. The method of claim 7 wherein the lung inflammation condition is adult respiratory distress syndrome.
10. The method of claim 7 wherein the lung inflammation condition is chronic obstructive pulmonary disease.